OncoDEEP: Now Testing All Solid Tumors For Gene Fusion And Unusual Splicing
OncoDNA has announced an upgrade of OncoDEEP, its tissue-based comprehensive biomarker test. As of 17th February, OncoDEEP will analyze gene fusions and unusual splicing events across all solid tumor types using the technology of RNA-seq. The upgrade will increase the chance of identifying actionable mutations and effective cancer treatment options for patients diagnosed with a stage 3 or stage 4 cancer.
In recent years, fusion genes and unusual splicing have gained significant recognition as biomarkers in oncology. There now exist several therapies that target these biomarkers. Some examples are the targeted therapy larotrectinib for patients diagnosed with a solid tumor that displays positive NTRK fusion, or the targeted therapy capmatinib for NSCLC patients with METex14 skipping mutations.
Unlike KRAS or PDL-1 which are biomarkers present in the DNA of tumor cells, gene fusion and unusual splicing biomarkers are visible at both DNA and RNA levels. Some may use methods such as FISH or PCR to detect RNA biomarkers. At OncoDNA, we have decided to use next-generation sequencing. The reasons are simple: NGS is the most robust, reliable and time-efficient technology for analyzing multiple biomarkers at the same time.
By targeting RNA biomarkers with NGS, OncoDNA brings clinicians an extra tool to consider the options of targeted therapy and hormone therapy in the treatment pathway of their patients. Precision medicine in oncology is advancing fast. 2021 was no exception, with 16 novel cancer drugs being approved by the FDA. With OncoDEEP, OncoDNA aims at helping clinicians to easily and rapidly identify which patients could benefit from these novel biomarker-associated therapies.
OncoDEEP is a centralized laboratory developed test since 2014. Compared to single biomarker tests, OncoDEEP is a comprehensive solution able to predict a patient’s eligibility to the latest cancer drugs in a single analysis. The test covers a very wide panel of genes and phenotypes known to be associated with cancer drugs – varying from standard therapies to experimental therapies. The panel includes complex, yet significant, genomic signatures like tumor mutational burden (TMB), homologous recombination deficiency (HRD) and microsatellite instability (MSI) that can determine whether immunotherapy or PARP inhibitors would work for a patient.